Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab. Blood 2024, 144: 7004-7004. DOI: 10.1182/blood-2024-199190.Peer-Reviewed Original ResearchTwice-weekly bortezomibTwice-weekly groupTwice-weekly dosingWeekly bortezomibMultiple myelomaPeripheral neuropathyBortezomib doseTwice-weeklyFrontline treatmentRate of PNDay 1Rates of peripheral neuropathyMedian follow-up timeTreatment efficacyBortezomib-induced peripheral neuropathyResponse rateWeeks groupBortezomib dose reductionBortezomib-containing regimensBortezomib-induced PNDose of bortezomibDiagnosis of MMIncidence of PNSingle-center studyFollow-up time